Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Anpac Bio-Medical Science Announced Updated Results From Its Cancer Test Follow-up Study In Over 18,000 Individuals In China. The Test Subjects Were Tested Using Anpac Bio's Cancer Differentiation Analysis (CDA) Method.

Author: Benzinga Newsdesk | February 22, 2023 08:52am
  • Health institutions including hospitals have reported that 2,837 individuals within the study were identified as cancer, pre-cancer and disease patients. 
  • The confirmed cancer cases contained 22 types of cancer, with the top five confirmed cancer types being colorectal cancer, lung cancer, stomach cancer, prostatic cancer and breast cancer. The study also identified patients with esophageal cancer which does not have a bio-marker. The confirmed cases also include 27 types of pre-cancer. 
  • Statistical analysis showed that there is also a strong correlation between CDA test score and cancer occurrence, with the higher the CDA value, the higher the cancer risk.
  • If the enrolled individuals are normalized to the sample size in which all three enrolled groups have the same amount of individuals, the confirmed cancer cases would be distributed as: 91.7% in the high risk group, 7.5% in the medium-cancer-risk group, and only 0.8% in the low risk group. 

Posted In: ANPC

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist